Clinical Trials

121 enrolled

Solid Tumor, Adult

NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Phase 2 Recruiting

170 enrolled

Solid Tumors

NCT05901285 2026-05-14

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

48 enrolled

Advanced Solid Tumor

NCT07182591 2026-05-14

A Study of DS5361b in Participants With Advanced Solid Tumors

192 enrolled

Advanced Solid Tumor

NCT07098988 2026-05-13

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Phase 2 Recruiting

107 enrolled

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT05438329 2026-05-12

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

1,123 enrolled

Advanced Solid Tumor

NCT02399371 2026-05-08

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Phase 2 Completed

65 enrolled 12 charts

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT05083481 2026-05-05

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

226 enrolled

Advanced Solid Tumors

NCT06057038 2026-05-05

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

42 enrolled

Malignant Solid Tumor

NCT06480552 2026-05-04

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

240 enrolled

Advanced Solid Tumors

NCT06795412 2026-05-04

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

220 enrolled

Advanced Solid Tumors

NCT04483778 2026-04-28

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

CNSDermatologicGastrointestinalGenitourinaryOther solid neoplasmSarcoma

68 enrolled

Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04123366 2026-04-22

MK-7339-007

Phase 2 Active not recruiting

300 enrolled

Solid Tumors

NCT05732831 2026-04-21

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

GastrointestinalOther solid neoplasmSarcomaThoracic

225 enrolled

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT07204340 2026-04-21

TLN-372 in Advanced KRAS Mutant Solid Tumors

240 enrolled

DermatologicHead & NeckOther solid neoplasmThoracic

KRAS Mutant Solid Tumors

NCT03881488 2026-04-17

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Phase 1 Completed

100 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT06576037 2026-04-16

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

128 enrolled

Solid Tumor

NCT04219254 2026-04-15

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

197 enrolled

Solid Tumor, Adult

NCT06470763 2026-04-14

EXPAND-1

240 enrolled

Advanced Solid Tumor

NCT06960395 2026-04-13

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

450 enrolled

Solid Tumor Malignancies

NCT03917381 2026-04-06

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

429 enrolled

Solid Tumors

NCT03126630 2026-04-01

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

49 enrolled 20 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant

NCT04234113 2026-03-27

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1 Terminated

115 enrolled 43 charts

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05763004 2026-03-27

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

140 enrolled

Solid Tumor, Adult

NCT05101070 2026-03-18

aCCeleR8-001

282 enrolled

Phase 1/2 Not yet recruiting

Solid Tumors

NCT07469774 2026-03-13

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

111 enrolled

Locally Advanced or Metastatic Solid Tumors

NCT04897022 2026-03-12

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

7 enrolled

Mesothelioma, Malignant

NCT06234397 2026-03-11

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

245 enrolled

Advanced or Metastatic Solid Tumors

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

410 enrolled

Select Advanced Solid Tumors

NCT03313778 2026-03-04

KEYNOTE-603

161 enrolled

Solid Tumors

NCT06994806 2026-03-03

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

84 enrolled